OncoMatch/Clinical Trials/NCT07762586
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)
Is NCT07762586 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Neoadjuvant Therapy for bladder cancer.
Treatment: Neoadjuvant Therapy — This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant therapy (NAT) followed by cystectomy compared to those receiving upfront cystectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CT2N0M0 (AJCC)
Excluded: Stage CN+, UNRESECTABLE BLADDER CANCER
cT2N0M0 bladder cancer based on pre-TURBT bimanual exam and cross-sectional imaging performed within 8 weeks of surgery or initiation of NAT. No cN+. No signs of extravesical disease on pre-TURBT conventional imaging. cT3 bladder cancer on pre-TURBT bimanual exam or with hydronephrosis on cross-sectional imaging...TURBT specimen with lymphovascular invasion (LVI) cT4 or unresectable bladder cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic treatment for non-urothelial malignancies
Prior history of systemic treatment for non-urothelial malignancies in the past three years, including chemotherapy and immunotherapy.
Lab requirements
Kidney function
creatinine clearance <30 ml/min
Liver function
Serum bilirubin > 1.5x upper limit of normal
Significant hepatic impairment (Serum bilirubin > 1.5x upper limit of normal). Significant renal impairment (creatinine clearance <30 ml/min).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute · New Brunswick, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07762586 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic treatment for non-urothelial malignancies disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT2N0M0 is required.
Is there an age limit?
Yes. Patients must be 90 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages